Researchers from the University of Liège and international collaborators have discovered an unexpected way to to stimulate the immune system against cancer: by subtly disrupting how tumour cells manufacture their proteins.

New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that OGM provided reliable and robust analytical performance with high sensitivity and specificity in detecting genetic alterations. In nearly 20% of cases, additional genetic variants were found that standard tests had missed. Although these current standard assays retain value in the diagnostic workflow, the study, appearing in The Journal of Molecular Diagnostics, published by Elsevier, shows that OGM offers an exceptional complement and can replace certain elements of the current testing algorithm.

A research team from the University of Tokyo and Tokyo University of Agriculture and Technology uncovered a new mechanism of Yaku’amide B, a deep-sea sponge-derived natural product. Using photoaffinity labeling, they found that yaku’amide B transiently binds CD9, inducing its degradation, in addition to inhibiting ATP synthase. This dual action suppresses cancer cell proliferation and migration, opening new avenues for anticancer drug development and protein degradation strategies.